02:56 PM EDT, 10/10/2025 (MT Newswires) -- GoodRx ( GDRX ) is reportedly in talks to join the TrumpRx website and the potential partnership would expand the company's offerings beyond its traditional direct discounts from pharmaceutical providers, Deutsche Bank said in a Friday note.

Deutsche Bank said that it remains skeptical of how the relationship would drive incremental volumes to GoodRx ( GDRX ) as it does not believe that pricing on TrumpRx will be better than that of pharmacy benefits managers, which the healthcare company already leverages.

The TrumpRx website is a direct-to-consumer website for drug purchases that is expected to go live in 2026, according to the note.

Deutsche Bank has a hold rating on GoodRx ( GDRX ) with a $6 price target.

Price: 4.30, Change: -0.35, Percent Change: -7.44